Compare POET & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POET | INVA |
|---|---|---|
| Founded | 1972 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2008 | 2000 |
| Metric | POET | INVA |
|---|---|---|
| Price | $8.08 | $23.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | ★ 28.5M | 522.3K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | $848.96 | $8.95 |
| Revenue Next Year | $700.00 | $12.65 |
| P/E Ratio | ★ N/A | $7.08 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $3.79 | $16.52 |
| 52 Week High | $15.50 | $25.15 |
| Indicator | POET | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 53.75 |
| Support Level | $5.40 | $23.28 |
| Resistance Level | $9.14 | $24.45 |
| Average True Range (ATR) | 1.37 | 0.63 |
| MACD | 0.20 | -0.09 |
| Stochastic Oscillator | 22.69 | 38.96 |
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.